Essential Partners’s Bicara Therapeutics BCAX Stock Holding History

Essential Partners’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$167	Hold	9	–	–	﹤0.01%	2629
2026 Q2	$267	Hold	9	–	–	﹤0.01%	2590
2026 Q1	$179	Hold	9	–	–	﹤0.01%	2629
2025 Q4	$151	Hold	9	–	–	﹤0.01%	2488
2025 Q3	$142	Buy	9 +5	+125%	+$56	﹤0.01%	2450
2025 Q2	$37	Buy	+4	New	+$48	﹤0.01%	2180

Other funds holding BCAX

RTM

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's BCAX Position: Q3 2026 in Review

Essential Partners held its Bicara Therapeutics (BCAX) position steady in Q3 2026 at 9 shares worth $167. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

Essential Partners first reported a position in BCAX in Q2 2025 and has held it in 6 quarters since. The position peaked at $267 in Q2 2026. 8 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

Essential Partners held 9 shares of Bicara Therapeutics worth $167 as of Q3 2026.
Essential Partners left its Bicara Therapeutics share count unchanged in Q3 2026.
Bicara Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2629 holding.
Essential Partners first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Bicara Therapeutics position peaked at $267 in Q2 2026.
8 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.